Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
about
Evolution of resistance to a last-resort antibiotic in Staphylococcus aureus via bacterial competitionMechanisms of drug resistance: daptomycin resistanceCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaTranscriptome analysis of responses to rhodomyrtone in methicillin-resistant Staphylococcus aureusStrain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-GenomeWhole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureusTuning the properties of the bacterial membrane with aminoacylated phosphatidylglycerol.Genetic basis for daptomycin resistance in enterococci.Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsAdditional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Increased cell wall teichoic acid production and D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates.Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approachCorrelation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation.In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.[Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.The role of Staphylococcal carotenogenesis in resistance to host defense peptides and in vivo virulence in experimental endocarditis model.Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapyA current perspective on daptomycin for the clinical microbiologist.Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.Bacterial membrane lipids in the action of antimicrobial agents.Bacterial resistance mechanisms against host defense peptides.Lipid complexes with cationic peptides and OAKs; their role in antimicrobial action and in the delivery of antimicrobial agents.Roles of tRNA in cell wall biosynthesis.Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis.Molecular analysis of methicillin-resistant Staphylococcus aureus dissemination among healthcare professionals and/or HIV patients from a tertiary hospital.Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.Targeting cell membrane adaptation as a novel antimicrobial strategy.Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and EnterococciDown-regulation of the two-component system and cell-wall biosynthesis-related genes was associated with the reversion to daptomycin susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus.Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.Antibiotics: Precious Goods in Changing Times.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin.Bactericidal activity of the human skin fatty acid cis-6-hexadecanoic acid on Staphylococcus aureus.A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus.
P2860
Q24490083-37F47D50-DE2C-4F8B-80DE-E85993C5E72CQ26779944-408A6703-6C2F-453D-94FD-F5E927E5D059Q26863225-DEDA6964-C08C-47D5-960E-95D94B4DF43DQ28484093-EBFAA9B7-F240-40A4-B5C5-264E5E33F053Q28553946-7581E550-BECF-4F63-BE03-C970F0532907Q28740293-9354DA6F-3096-44A0-AEE8-993A654166CDQ33507347-24E76A5D-0F8B-4680-91FC-EF5753834FB3Q33876255-5F53D630-FE55-4375-ADFE-3B6C2D8C1A26Q34045376-B7256FC0-BA7C-40DC-A73E-41133462177CQ34648042-C2F1CD45-E51B-4CDE-B43D-9FDD9E17677AQ34779009-FAC27557-C6F3-499B-A3D3-58B78655E253Q34932588-57888C9C-C8F2-4D2A-966F-8F8BFCB3460AQ35096905-31572062-DC91-4967-A87A-DFC8F13D0FE8Q35139449-93A8294E-85C0-4FB0-A5B3-E98FAF214ACAQ35191555-350E7C6B-F104-46F8-A739-9936C11AC80DQ35619094-CE52FA97-1EC4-4553-AB46-D4EB9920DE79Q35746096-6167C3F6-3647-458C-9324-B0F176ED44A8Q36158472-5FF1DA61-E1E1-4F46-B8D6-32DD19D051E0Q36167509-E246B031-2AFA-4A69-94D0-C9A75FDF14F9Q36401160-A16958D3-BD90-41FC-8E5F-106DB4FB0E1FQ37238371-D64D0827-0B2A-4867-8AAF-7D2E812DBA5FQ37263289-EEBC0AA1-153A-44E3-9378-0CB23CF504CFQ37417749-CDB51F82-891C-493C-82E3-8A54056AAF1EQ37863657-D5E4F697-1FC0-4E32-B2B6-487ACA3D8509Q37874201-6FB93748-B3B7-4F02-8AFF-448422B30DB0Q37875766-CF3D0E5F-3675-4319-9698-C0D6BBBBFAFCQ37977400-7E9E501E-8BBA-41F4-91F8-1E69FD3D0312Q38282693-6BAD645C-AA47-4923-A023-6A11699F5E84Q38380412-D60EF031-2883-4766-8310-1A0E789CEE8FQ38626860-89A7F4AD-1A4A-4CCE-9240-C27FED8A4FCBQ38908726-C51A9C63-2B02-4190-8B4E-FB0920999C42Q38942573-9B1EE912-4293-45B6-BDC7-B2C6DF593B5FQ40224178-801AEA9F-06DB-40C2-BA30-0C3AB057CFB1Q40264307-9DB89901-93E4-4F29-8951-BCA1F7C521F1Q40327375-A0C15744-BAD2-405B-9AAD-937F83A3E45DQ40441124-F4584D90-3126-4FD4-B94A-E7BE03D05631Q40631566-B341DF18-F7C0-4624-8EF5-B8B34B19FC9BQ40758601-E7B2EB16-3C07-411B-9C60-77BDD199CFEBQ41078072-29CB9330-FFA5-449F-9782-8F5CDDD30E74Q41145530-F24EE105-57B2-4CE2-9723-03645865E234
P2860
Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Serial daptomycin selection ge ...... omycin-intermediate phenotype.
@en
type
label
Serial daptomycin selection ge ...... omycin-intermediate phenotype.
@en
prefLabel
Serial daptomycin selection ge ...... omycin-intermediate phenotype.
@en
P2860
P356
P1476
Serial daptomycin selection ge ...... comycin-intermediate phenotype
@en
P2093
Keiichi Hiramatsu
Longzhu Cui
P2860
P304
P356
10.1128/AAC.00417-08
P407
P577
2008-09-29T00:00:00Z